In Latvia, a breakthrough virotherapy called Rigvir has been doing wonders since 2004. This new treatment breaks down cancer cells and stimulates the immune system.

The treatment has been used on a wide variety of cancers including melanoma, colorectal, pancreatic, bladder, kidney, prostate, lung, uterine, lymphosarcoma, etc.

This explains why it is also unleashing passions overseas: At the end of July, the Hope4Cancer Institute in California, USA, issued a press release announcing that it was now the first institution in the country to offer Rigvir virotherapy to its patients.

Many cancer patients across the world are increasingly beginning to accept that conventional treatment may not be for them. Chemotherapy, in particular, tends to deplete one’s quality of life to great lengths rather than improve it, and this is where Rigvir comes in.

Rigvir is an ECHO-7 virus strain, which could be found naturally in the intestines of young children. The virus selectively targets malignant cells, which it enters before multiplying through a process called oncolysis – eventually destroying the cancerous cell. Moreover, the virus makes the cancer visible to the patient’s immune system, enabling the latter to fight back.

It is administered by means of a series of injections over the course of at least three years. Although the International Virotherapy Center- which develops and promotes the treatment – mentions mild side effects on its website, it specifies that the most common side-effect is a subfebrile temperature lasting one to three days. This contrasts with chemotherapy, infamous for the harm it causes to healthy cells.

Rigvir is:

  • a registered anticancer drug from the International Virotherapy Center.
  • supported by a legacy of over 50 years of research that includes numerous clinical trials on hundreds of patients.
  • has a demonstrated selective efficacy against a variety of tumours as well as powerful immune system modulating properties that make the cancer vulnerable to further attack.
  • has an exceptional safety profile – non-pathogenic (does not replicate or cause disease in humans), phenomenal therapeutic index, unrivaled by standard chemotherapy and radiotherapy treatments.

It is also important to note that for some people living with cancer, Rigvir could be an important factor when used during intermissions of standard treatment in controlling the cancer in their body.

To find out more about Rigvir or other alternative treatment options, please contact us.

Source: Medical Xpress